Quality-of-Life Assessment for Acute Leukemia

City of Hope Medical Center, Duarte, CA
Acute Leukemia+3 More ConditionsQuality-of-Life Assessment - Other
Eligibility
Any Age
All Sexes

Study Summary

This trial is testing whether an eHealth intervention can help reduce learning disparities for children with cancer.

Eligible Conditions
  • Acute Leukemia
  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Lymphoblastic Lymphoma

Treatment Effectiveness

Study Objectives

1 Primary · 9 Secondary · Reporting Duration: Up to 5 years

Year 1
Child's improvement in academic functioning
Year 1
Parenting pro-learning efficacy (Parents)
Baseline, time 2, time 3
Mean of item scores from the Student Academic Self-efficacy questionnaire
Mean of item scores from the Student Intrinsic Motivation to Learn questionnaire
Up to 5 years
Attention performance (Child)
Anxiety
Knowledge of pro-learning parenting (Parents)
Objective academic performance (Child)
Parent-reported functioning of child (Child)
Use of learning strategies (Child)

Trial Safety

Side Effects for

Arm II (gp100 Antigen in Montanide IDA-51 and Aldesleukin)
48%Blood or bone marrow
42%Metabolic or laboratory-testing result
40%Hepatic
36%General
28%Constitutional symptoms
26%Neurologic
22%Pulmonary
21%Gastrointestinal
19%Renal or genitourinary
19%Arrhythmia
13%Pain
8%Infection or febrile neutropenia
7%Skin
7%Musculoskeletal
2%Death
This histogram enumerates side effects from a completed 2011 Phase 3 trial (NCT00019682) in the Arm II (gp100 Antigen in Montanide IDA-51 and Aldesleukin) ARM group. Side effects include: Blood or bone marrow with 48%, Metabolic or laboratory-testing result with 42%, Hepatic with 40%, General with 36%, Constitutional symptoms with 28%.

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

2 Treatment Groups

Arm II (usual care)
1 of 2
Arm I (high intensity e-Health program)
1 of 2

Active Control

Experimental Treatment

332 Total Participants · 2 Treatment Groups

Primary Treatment: Quality-of-Life Assessment · No Placebo Group · N/A

Arm I (high intensity e-Health program)Experimental Group · 4 Interventions: Best Practice, Internet-Based Intervention, Quality-of-Life Assessment, Questionnaire Administration · Intervention Types: Other, Other, Other, Other
Arm II (usual care)ActiveComparator Group · 3 Interventions: Best Practice, Quality-of-Life Assessment, Questionnaire Administration · Intervention Types: Other, Other, Other

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 5 years

Who is running the clinical trial?

City of Hope Medical CenterLead Sponsor
535 Previous Clinical Trials
2,249,622 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,282 Previous Clinical Trials
41,235,021 Total Patients Enrolled
Sunita K PatelPrincipal InvestigatorCity of Hope Medical Center

Eligibility Criteria

Age Any Age · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
The child can speak and understand English (but can also speak another language).

Frequently Asked Questions

Is enrollment open for this experiment currently?

"In accordance with the data hosted on clinicaltrials.gov, this medical trial is still open to participants and was originally posted on August 12th 2022 before recently being amended on the 15th of that month." - Anonymous Online Contributor

Unverified Answer

How many individuals are taking part in this research project?

"Affirmative. According to clinicaltrials.gov, this investigation commenced on August 12th 2022 and is actively recruiting patients at the moment; it was most recently updated on August 15th of the same year. 342 individuals need to be found from a single medical institution in order for the trial to come to fruition." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.